HEADER VIRAL PROTEIN 02-FEB-23 8CES TITLE CRYSTAL STRUCTURE OF MONKEYPOX VIRUS METHYLTRANSFERASE VP39 IN COMPLEX TITLE 2 WITH INHIBITOR TO500 COMPND MOL_ID: 1; COMPND 2 MOLECULE: CAP-SPECIFIC MRNA (NUCLEOSIDE-2'-O-)-METHYLTRANSFERASE; COMPND 3 CHAIN: A, B; COMPND 4 EC: 2.1.1.57; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: MONKEYPOX VIRUS; SOURCE 3 ORGANISM_TAXID: 10244; SOURCE 4 GENE: PAPS, MPXV-M2940_FCT-085, MPXV-M2957_LAGOS-085, MPXV- SOURCE 5 M3021_DELTA-085, MPXV-M5312_HM12_RIVERS-085, MPXV-M5320_M15_BAYELSA- SOURCE 6 078, MPXV-NIG_SEV71_2_82-080, MPXV-SINGAPORE-085, MPXV-UK_P1-085, SOURCE 7 MPXV-UK_P2-085, MPXV-UK_P3-085, MPXV-W_NIGERIA-080, MPXV297957_076, SOURCE 8 MPXV298464_067, PDLMKLCO_00090; SOURCE 9 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 10 EXPRESSION_SYSTEM_TAXID: 469008 KEYWDS VIRAL, METHYLTRANSFERASE, VP39, MONKEYPOX, MPOX, CAPPING, ENZYME, KEYWDS 2 INHIBITOR, VIRAL PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR M.KLIMA,J.SILHAN,E.BOURA REVDAT 2 03-MAY-23 8CES 1 JRNL REVDAT 1 05-APR-23 8CES 0 JRNL AUTH J.SILHAN,M.KLIMA,T.OTAVA,P.SKVARA,D.CHALUPSKA,K.CHALUPSKY, JRNL AUTH 2 J.KOZIC,R.NENCKA,E.BOURA JRNL TITL DISCOVERY AND STRUCTURAL CHARACTERIZATION OF MONKEYPOX VIRUS JRNL TITL 2 METHYLTRANSFERASE VP39 INHIBITORS REVEAL SIMILARITIES TO JRNL TITL 3 SARS-COV-2 NSP14 METHYLTRANSFERASE. JRNL REF NAT COMMUN V. 14 2259 2023 JRNL REFN ESSN 2041-1723 JRNL PMID 37080993 JRNL DOI 10.1038/S41467-023-38019-1 REMARK 2 REMARK 2 RESOLUTION. 2.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.20_4459 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : GEOSTD + MONOMER LIBRARY + CDL V1.2 REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 48.93 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.340 REMARK 3 COMPLETENESS FOR RANGE (%) : 91.1 REMARK 3 NUMBER OF REFLECTIONS : 21840 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.238 REMARK 3 R VALUE (WORKING SET) : 0.236 REMARK 3 FREE R VALUE : 0.282 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.010 REMARK 3 FREE R VALUE TEST SET COUNT : 1094 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 48.9300 - 5.0000 0.98 2971 157 0.1907 0.2211 REMARK 3 2 5.0000 - 3.9700 0.98 2814 148 0.1689 0.2119 REMARK 3 3 3.9700 - 3.4700 0.91 2611 138 0.2815 0.3276 REMARK 3 4 3.4700 - 3.1500 0.96 2734 144 0.2753 0.3226 REMARK 3 5 3.1500 - 2.9200 0.94 2637 138 0.2600 0.2812 REMARK 3 6 2.9200 - 2.7500 0.88 2455 130 0.2668 0.3595 REMARK 3 7 2.7500 - 2.6100 0.82 2306 122 0.3152 0.3819 REMARK 3 8 2.6100 - 2.5000 0.79 2218 117 0.3059 0.3973 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.10 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.373 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 28.772 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 37.90 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 41.05 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.005 4750 REMARK 3 ANGLE : 0.692 6450 REMARK 3 CHIRALITY : 0.045 713 REMARK 3 PLANARITY : 0.006 817 REMARK 3 DIHEDRAL : 12.854 1780 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 8CES COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 03-FEB-23. REMARK 100 THE DEPOSITION ID IS D_1292128223. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 11-JAN-23 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : BESSY REMARK 200 BEAMLINE : 14.1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9184 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS XDSAPP V3.0 REMARK 200 DATA SCALING SOFTWARE : XDS XDSAPP V3.0 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 22141 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.500 REMARK 200 RESOLUTION RANGE LOW (A) : 48.930 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 91.1 REMARK 200 DATA REDUNDANCY : 6.200 REMARK 200 R MERGE (I) : 0.18960 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 8.4700 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.59 REMARK 200 COMPLETENESS FOR SHELL (%) : 78.5 REMARK 200 DATA REDUNDANCY IN SHELL : 5.50 REMARK 200 R MERGE FOR SHELL (I) : 1.23900 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.270 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER 2.8.3 REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 47.06 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.32 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 200 MM LITHIUM CITRATE, 14.5% (W/V) REMARK 280 PEG 3350, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.80300 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 77.02700 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 42.02750 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 77.02700 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.80300 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 42.02750 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLU A 23 REMARK 465 PRO A 24 REMARK 465 GLU A 25 REMARK 465 SER A 26 REMARK 465 ALA A 27 REMARK 465 ASN A 28 REMARK 465 GLU A 29 REMARK 465 VAL A 30 REMARK 465 ALA A 31 REMARK 465 LYS A 32 REMARK 465 LYS A 33 REMARK 465 LYS A 142 REMARK 465 ARG A 143 REMARK 465 GLY A 144 REMARK 465 GLY A 145 REMARK 465 ASN A 146 REMARK 465 GLY A 216 REMARK 465 GLU A 217 REMARK 465 ASN A 218 REMARK 465 THR A 298 REMARK 465 THR A 299 REMARK 465 SER A 300 REMARK 465 THR A 301 REMARK 465 GLU A 302 REMARK 465 LYS A 303 REMARK 465 VAL A 304 REMARK 465 SER A 305 REMARK 465 HIS A 306 REMARK 465 GLU A 307 REMARK 465 MET B 1 REMARK 465 ASP B 2 REMARK 465 PRO B 24 REMARK 465 GLU B 25 REMARK 465 SER B 26 REMARK 465 ALA B 27 REMARK 465 ASN B 28 REMARK 465 GLU B 29 REMARK 465 VAL B 30 REMARK 465 ALA B 31 REMARK 465 LYS B 32 REMARK 465 LYS B 142 REMARK 465 ARG B 143 REMARK 465 GLY B 144 REMARK 465 GLY B 145 REMARK 465 ASN B 146 REMARK 465 THR B 215 REMARK 465 GLY B 216 REMARK 465 GLU B 217 REMARK 465 ASN B 218 REMARK 465 THR B 298 REMARK 465 THR B 299 REMARK 465 SER B 300 REMARK 465 THR B 301 REMARK 465 GLU B 302 REMARK 465 LYS B 303 REMARK 465 VAL B 304 REMARK 465 SER B 305 REMARK 465 HIS B 306 REMARK 465 GLU B 307 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 90 CD CE NZ REMARK 470 ARG A 107 CG CD NE CZ NH1 NH2 REMARK 470 GLU A 147 CG CD OE1 OE2 REMARK 470 LYS A 186 CD CE NZ REMARK 470 ARG A 220 CG CD NE CZ NH1 NH2 REMARK 470 LYS B 8 CG CD CE NZ REMARK 470 GLU B 14 CG CD OE1 OE2 REMARK 470 ASN B 18 CG OD1 ND2 REMARK 470 LEU B 20 CG CD1 CD2 REMARK 470 ASP B 21 CG OD1 OD2 REMARK 470 GLU B 23 CG CD OE1 OE2 REMARK 470 LYS B 33 CG CD CE NZ REMARK 470 LYS B 52 CG CD CE NZ REMARK 470 ARG B 140 CG CD NE CZ NH1 NH2 REMARK 470 GLU B 147 CG CD OE1 OE2 REMARK 470 LYS B 241 CG CD CE NZ REMARK 470 LYS B 246 CG CD CE NZ REMARK 470 LYS B 274 CG CD CE NZ REMARK 470 ARG B 292 CG CD NE CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO A 130 35.29 -98.71 REMARK 500 ASP A 138 31.07 -140.69 REMARK 500 ILE A 185 -55.13 -128.11 REMARK 500 ILE A 242 -63.24 -93.93 REMARK 500 ASP B 108 0.12 -68.40 REMARK 500 PRO B 202 153.68 -46.69 REMARK 500 REMARK 500 REMARK: NULL DBREF1 8CES A 1 307 UNP A0A0F6N8X1_MONPV DBREF2 8CES A A0A0F6N8X1 1 307 DBREF1 8CES B 1 307 UNP A0A0F6N8X1_MONPV DBREF2 8CES B A0A0F6N8X1 1 307 SEQRES 1 A 307 MET ASP VAL VAL SER LEU ASP LYS PRO PHE MET TYR PHE SEQRES 2 A 307 GLU GLU ILE ASP ASN GLU LEU ASP TYR GLU PRO GLU SER SEQRES 3 A 307 ALA ASN GLU VAL ALA LYS LYS LEU PRO TYR GLN GLY GLN SEQRES 4 A 307 LEU LYS LEU LEU LEU GLY GLU LEU PHE PHE LEU SER LYS SEQRES 5 A 307 LEU GLN ARG HIS GLY ILE LEU ASP GLY ALA THR VAL VAL SEQRES 6 A 307 TYR ILE GLY SER ALA PRO GLY THR HIS ILE ARG TYR LEU SEQRES 7 A 307 ARG ASP HIS PHE TYR ASN LEU GLY VAL ILE ILE LYS TRP SEQRES 8 A 307 MET LEU ILE ASP GLY ARG HIS HIS ASP PRO ILE LEU ASN SEQRES 9 A 307 GLY LEU ARG ASP VAL THR LEU VAL THR ARG PHE VAL ASP SEQRES 10 A 307 GLU GLU TYR LEU ARG SER ILE LYS LYS GLN LEU HIS PRO SEQRES 11 A 307 SER LYS ILE ILE LEU ILE SER ASP VAL ARG SER LYS ARG SEQRES 12 A 307 GLY GLY ASN GLU PRO SER THR ALA ASP LEU LEU SER ASN SEQRES 13 A 307 TYR ALA LEU GLN ASN VAL MET ILE SER ILE LEU ASN PRO SEQRES 14 A 307 VAL ALA SER SER LEU LYS TRP ARG CYS PRO PHE PRO ASP SEQRES 15 A 307 GLN TRP ILE LYS ASP PHE TYR ILE PRO HIS GLY ASN LYS SEQRES 16 A 307 MET LEU GLN PRO PHE ALA PRO SER TYR SER ALA GLU MET SEQRES 17 A 307 ARG LEU LEU SER ILE TYR THR GLY GLU ASN MET ARG LEU SEQRES 18 A 307 THR ARG VAL THR LYS SER ASP ALA VAL ASN TYR GLU LYS SEQRES 19 A 307 LYS MET TYR TYR LEU ASN LYS ILE VAL ARG ASN LYS VAL SEQRES 20 A 307 VAL ILE ASN PHE ASP TYR PRO ASN GLN GLU TYR ASP TYR SEQRES 21 A 307 PHE HIS MET TYR PHE MET LEU ARG THR VAL TYR CYS ASN SEQRES 22 A 307 LYS THR PHE PRO THR THR LYS ALA LYS ILE LEU PHE LEU SEQRES 23 A 307 GLN GLN SER ILE PHE ARG PHE LEU ASN ILE PRO THR THR SEQRES 24 A 307 SER THR GLU LYS VAL SER HIS GLU SEQRES 1 B 307 MET ASP VAL VAL SER LEU ASP LYS PRO PHE MET TYR PHE SEQRES 2 B 307 GLU GLU ILE ASP ASN GLU LEU ASP TYR GLU PRO GLU SER SEQRES 3 B 307 ALA ASN GLU VAL ALA LYS LYS LEU PRO TYR GLN GLY GLN SEQRES 4 B 307 LEU LYS LEU LEU LEU GLY GLU LEU PHE PHE LEU SER LYS SEQRES 5 B 307 LEU GLN ARG HIS GLY ILE LEU ASP GLY ALA THR VAL VAL SEQRES 6 B 307 TYR ILE GLY SER ALA PRO GLY THR HIS ILE ARG TYR LEU SEQRES 7 B 307 ARG ASP HIS PHE TYR ASN LEU GLY VAL ILE ILE LYS TRP SEQRES 8 B 307 MET LEU ILE ASP GLY ARG HIS HIS ASP PRO ILE LEU ASN SEQRES 9 B 307 GLY LEU ARG ASP VAL THR LEU VAL THR ARG PHE VAL ASP SEQRES 10 B 307 GLU GLU TYR LEU ARG SER ILE LYS LYS GLN LEU HIS PRO SEQRES 11 B 307 SER LYS ILE ILE LEU ILE SER ASP VAL ARG SER LYS ARG SEQRES 12 B 307 GLY GLY ASN GLU PRO SER THR ALA ASP LEU LEU SER ASN SEQRES 13 B 307 TYR ALA LEU GLN ASN VAL MET ILE SER ILE LEU ASN PRO SEQRES 14 B 307 VAL ALA SER SER LEU LYS TRP ARG CYS PRO PHE PRO ASP SEQRES 15 B 307 GLN TRP ILE LYS ASP PHE TYR ILE PRO HIS GLY ASN LYS SEQRES 16 B 307 MET LEU GLN PRO PHE ALA PRO SER TYR SER ALA GLU MET SEQRES 17 B 307 ARG LEU LEU SER ILE TYR THR GLY GLU ASN MET ARG LEU SEQRES 18 B 307 THR ARG VAL THR LYS SER ASP ALA VAL ASN TYR GLU LYS SEQRES 19 B 307 LYS MET TYR TYR LEU ASN LYS ILE VAL ARG ASN LYS VAL SEQRES 20 B 307 VAL ILE ASN PHE ASP TYR PRO ASN GLN GLU TYR ASP TYR SEQRES 21 B 307 PHE HIS MET TYR PHE MET LEU ARG THR VAL TYR CYS ASN SEQRES 22 B 307 LYS THR PHE PRO THR THR LYS ALA LYS ILE LEU PHE LEU SEQRES 23 B 307 GLN GLN SER ILE PHE ARG PHE LEU ASN ILE PRO THR THR SEQRES 24 B 307 SER THR GLU LYS VAL SER HIS GLU HET UH2 A 401 37 HET UH2 B 401 37 HETNAM UH2 (2~{S})-2-AZANYL-4-[[(2~{S},3~{S},4~{R},5~{R})-5-[4- HETNAM 2 UH2 AZANYL-5-[2-(1~{H}-BENZIMIDAZOL-2-YL) HETNAM 3 UH2 ETHYNYL]PYRROLO[2,3-D]PYRIMIDIN-7-YL]-3,4- HETNAM 4 UH2 BIS(OXIDANYL)OXOLAN-2-YL]METHYLSULFANYL]BUTANOIC ACID FORMUL 3 UH2 2(C24 H25 N7 O5 S) FORMUL 5 HOH *42(H2 O) HELIX 1 AA1 TYR A 12 ILE A 16 5 5 HELIX 2 AA2 TYR A 36 HIS A 56 1 21 HELIX 3 AA3 HIS A 74 LEU A 85 1 12 HELIX 4 AA4 ASP A 100 ASN A 104 5 5 HELIX 5 AA5 ASP A 117 HIS A 129 1 13 HELIX 6 AA6 SER A 149 ASN A 168 1 20 HELIX 7 AA7 PHE A 180 TRP A 184 5 5 HELIX 8 AA8 THR A 225 ILE A 242 1 18 HELIX 9 AA9 VAL A 243 LYS A 246 5 4 HELIX 10 AB1 GLU A 257 ARG A 268 1 12 HELIX 11 AB2 THR A 278 ASN A 295 1 18 HELIX 12 AB3 TYR B 12 ILE B 16 5 5 HELIX 13 AB4 TYR B 36 HIS B 56 1 21 HELIX 14 AB5 HIS B 74 LEU B 85 1 12 HELIX 15 AB6 ASP B 100 ASN B 104 5 5 HELIX 16 AB7 ASP B 117 HIS B 129 1 13 HELIX 17 AB8 SER B 149 ASN B 168 1 20 HELIX 18 AB9 PHE B 180 TRP B 184 5 5 HELIX 19 AC1 THR B 225 ILE B 242 1 18 HELIX 20 AC2 VAL B 243 LYS B 246 5 4 HELIX 21 AC3 GLU B 257 ARG B 268 1 12 HELIX 22 AC4 THR B 278 ASN B 295 1 18 SHEET 1 AA1 2 VAL A 3 VAL A 4 0 SHEET 2 AA1 2 VAL A 247 VAL A 248 1 O VAL A 247 N VAL A 4 SHEET 1 AA2 7 VAL A 109 THR A 113 0 SHEET 2 AA2 7 LYS A 90 ASP A 95 1 N LEU A 93 O THR A 110 SHEET 3 AA2 7 THR A 63 ILE A 67 1 N VAL A 64 O LYS A 90 SHEET 4 AA2 7 ILE A 133 SER A 137 1 O ILE A 134 N VAL A 65 SHEET 5 AA2 7 ALA A 171 TRP A 176 1 O SER A 173 N SER A 137 SHEET 6 AA2 7 MET A 208 ILE A 213 -1 O LEU A 210 N LEU A 174 SHEET 7 AA2 7 ASN A 194 MET A 196 -1 N ASN A 194 O LEU A 211 SHEET 1 AA3 2 PHE A 188 PRO A 191 0 SHEET 2 AA3 2 LEU A 221 VAL A 224 -1 O THR A 222 N ILE A 190 SHEET 1 AA4 7 VAL B 109 THR B 113 0 SHEET 2 AA4 7 ILE B 89 ASP B 95 1 N LEU B 93 O VAL B 112 SHEET 3 AA4 7 ALA B 62 ILE B 67 1 N TYR B 66 O ILE B 94 SHEET 4 AA4 7 ILE B 133 SER B 137 1 O ILE B 136 N VAL B 65 SHEET 5 AA4 7 ALA B 171 TRP B 176 1 O SER B 173 N SER B 137 SHEET 6 AA4 7 MET B 208 ILE B 213 -1 O LEU B 210 N LEU B 174 SHEET 7 AA4 7 ASN B 194 MET B 196 -1 N ASN B 194 O LEU B 211 SHEET 1 AA5 2 PHE B 188 PRO B 191 0 SHEET 2 AA5 2 LEU B 221 VAL B 224 -1 O THR B 222 N ILE B 190 CISPEP 1 ALA A 70 PRO A 71 0 2.66 CISPEP 2 HIS A 129 PRO A 130 0 2.44 CISPEP 3 ALA B 70 PRO B 71 0 -5.13 CISPEP 4 HIS B 129 PRO B 130 0 9.43 CRYST1 51.606 84.055 154.054 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019378 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011897 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006491 0.00000